3122-85-8 Usage
Uses
Used in Organic Synthesis:
Pyrimidine, 4-amino-2-(ethoxymethyl)(8CI) is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure and functional groups allow for versatile chemical reactions, facilitating the synthesis of a wide range of compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Pyrimidine, 4-amino-2-(ethoxymethyl)(8CI) is utilized as a key intermediate in the development of pharmaceutical drugs. Its potential applications include the synthesis of novel therapeutic agents targeting various diseases and conditions.
Used in Pharmaceutical Drug Development:
Pyrimidine, 4-amino-2-(ethoxymethyl)(8CI) is employed as a precursor in the synthesis of new pharmaceutical drugs. Its unique chemical properties and potential biological activity make it a promising candidate for the development of innovative therapeutics.
Used in Agrochemicals:
Pyrimidine, 4-amino-2-(ethoxymethyl)(8CI) also has potential applications in the agrochemical industry, where it can be used as a building block for the synthesis of new agrochemicals, such as pesticides and herbicides. Its unique structure and properties may contribute to the development of more effective and environmentally friendly agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 3122-85-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,1,2 and 2 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3122-85:
(6*3)+(5*1)+(4*2)+(3*2)+(2*8)+(1*5)=58
58 % 10 = 8
So 3122-85-8 is a valid CAS Registry Number.
3122-85-8Relevant academic research and scientific papers
Synthesis and biological evaluations of new pyrrolo[2,3-b]pyrimidine as SDI analogs
Guillard, Jerome,Viaud-Massuard, Marie-Claude
, p. 1163 - 1189 (2008/12/20)
The synthesis of new pyrrolo[2,3-d]pyrimidines variously substituted on the N-1 and C-2 atoms are described. Access to these compounds, which have modest activity compared with the first inhibitor SDI, involves, as the key step, the formation of a pyrrolopyrimidine skeleton from the 5-amino-2-(methoxymethyl)pyrimidine.
11B-HSD1 inhibitors for the treatment of diabetes
-
Page/Page column 12, (2008/06/13)
Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
